CD19 and Miyoshi myopathy: Furthermore, MMG49 antigen was also highly expressed in CD19-positive clonotypic B cells, which are candidates for MM precursor cells [7], suggesting that the MMG49 antigen is a good therapeutic target for eradicating the whole MM clones.